Tacrolimus improved the pregnancy outcomes of patients with refractory recurrent spontaneous abortion and immune bias disorders: a randomized controlled trial
Authors:
- 13 March 2023
- journal article
- research article
- Published by Springer Nature in European Journal of Clinical Pharmacology
- Vol. 79 (5) , 627-634
Abstract
Objective To investigate the effect of tacrolimus treatment on refractory recurrent spontaneous abortion (RSA) patients with elevated serum IL-33/ST2 levels. Methods This study was a randomized controlled trial (RCT) of refractory RSA patients with elevated peripheral blood IL-33/ST2 levels or an elevated Th1/Th2 cell ratio. A total of 149 women were enrolled, each of whom had had at least 3 serial miscarriages and was confirmed to have elevated peripheral blood IL-33/ST2 levels or an elevated Th1/Th2 cell ratio. These women were randomly divided into two groups. The tacrolimus group (n = 75) received basic therapy with the addition of tacrolimus (Prograf). Tacrolimus was administered at a dose of 0.05 ~ 0.1 mg/kg/day from the end of the menstrual period to the beginning of the next menstrual period or to the 10th week of pregnancy. In contrast, basic therapy with the addition of placebo was given to the placebo group (n = 74). The main study outcome was the delivery of healthy newborns without deformities. Results A total of 60 (80.00%) patients in the tacrolimus group and 47 (63.51%) patients in the placebo group delivered healthy newborns [P = 0.03, odds ratio = 2.30; 95% confidence interval (1.10 ~ 4.81)]. The peripheral blood IL-33/ST2 levels and Th1/Th2 cell ratio of the tacrolimus group were much lower than those of the placebo group (P < 0.05). Conclusion We validated our previous finding that serum IL-33 and sST2 concentrations are related to RSA. Immunosuppressive treatment with tacrolimus was demonstrated to be a promising method to treat refractory RSA with immune bias disorders.Keywords
Funding Information
- China Health Promotion Foundation (XM_2020_011_0245_09)
- National Natural Science Foundation of China (81800601)
- China Postdoctoral Science Foundation (2019M652333)
- Natural Science Foundation of Shandong Province (ZR2020QH060)
- Qingdao Key Health Discipline Development Fund
This publication has 34 references indexed in Scilit:
- Disordered IL-33/ST2 Activation in Decidualizing Stromal Cells Prolongs Uterine Receptivity in Women with Recurrent Pregnancy LossPLOS ONE, 2012
- Interleukin-33 in the human placentaThe Journal of Maternal-Fetal & Neonatal Medicine, 2012
- Maternal serum interleukin-33 and soluble ST2 across early pregnancy, and their association with miscarriageJournal of Reproductive Immunology, 2012
- Treating inflammation by blocking interleukin-1 in a broad spectrum of diseasesNature Reviews Drug Discovery, 2012
- IL-33 and ST2 in Atopic Dermatitis: Expression Profiles and Modulation by Triggering FactorsJournal of Investigative Dermatology, 2012
- ST2 and IL-33 in Pregnancy and Pre-EclampsiaPLOS ONE, 2011
- IL-33 amplifies both Th1- and Th2-type responses through its activity on human basophils, allergen-reactive Th2 cells, iNKT and NK CellsInternational Immunology, 2008
- Immunotherapy for recurrent miscarriage2006
- Cytokines, chemokines and growth factors in endometrium related to implantationHuman Reproduction Update, 2005
- Th1/Th2 Paradigm in Pregnancy: Paradigm Lost?International Archives of Allergy and Immunology, 2004